BPC-157 vs TB-500: What the Healing Pair Actually Is

These two get sold together, talked about together, and described in almost the same words. Search either one and the other shows up within a paragraph, usually with “synergy” nearby.

They are not the same kind of thing. They work in different ways, they are taken on schedules that look nothing alike, and one of them is not the molecule its research belongs to.

Here is what each one is, what the studies actually found, and where the popular story stops matching the papers.

What BPC-157 is

BPC-157 is a lab-made chain of 15 amino acids, based on a protein found in stomach juice. The name is short for Body Protection Compound. That tells you what its developers hoped for, and nothing about whether it works.

The idea behind it is that it helps the body grow new blood vessels. New blood vessels mean more blood supply to an injured area, and more blood supply is part of how anything heals. In lab dishes it also made tendon cells more responsive to growth hormone, and that is the explanation usually given for the tendon results.

What TB-500 is

TB-500 covers two molecules that are not the same size or the same thing, and telling them apart is the most useful thing in this guide.

Thymosin beta-4 is a protein your body already makes, found in most of your cells. It is 43 amino acids long. Its job involves actin, the internal scaffolding that gives a cell its shape and lets it crawl from place to place. Crawling cells are how a wound closes.

TB-500 is a lab-made piece of that protein, seven amino acids long.

Seven out of forty-three. It copies the one short stretch that grabs onto the scaffolding and leaves the rest behind, which makes it a related molecule rather than the same one under a shorter name.

The identity problem

Every healing number you see quoted for TB-500 comes from the full 43 amino acid protein.

The most-repeated figures are from a 1999 study on rats: new skin grew over a wound about 42% faster by day four and up to 61% faster by day seven compared with saline, and wounds closed about 11% more by day seven. In lab dishes, the same protein made skin cells move two to three times as much.

Those are real results from a real paper, and every one of them describes the full protein.

The same goes for every human study. The full protein has been tested in people several times, and the seven amino acid piece has not been in any of them.

What the piece keeps is the part that grabs the cell scaffolding, which is what drives cells to move. What it loses is a section linked to reducing scar tissue and a section linked to keeping cells alive under stress. Nobody has run a study comparing the piece against the full protein in a living body, so nobody knows how much of the effect carries over.

One practical warning. Suppliers use “thymosin beta-4 fragment” loosely, and it does not always mean the same piece. Some products sold under that description are a completely different section of the protein.

What the human studies on the full protein found

The summary you will usually get is that thymosin beta-4 worked in people. The record is messier.

Dry eye

Eye drops made from the full protein went through three studies, ending in a large one. It did not hit the main results it was testing for. One smaller measure, how gritty people’s eyes felt, did improve.

Corneal damage

A small US study of 18 patients found more of them healed on the drug than on placebo, but the result sat right on the line of what counts as meaningful, and a larger European study afterwards failed outright.

Heart attack

In 2025, a study of 96 heart attack patients tested an injected version of the full protein. Overall, it did not reduce the amount of damaged heart muscle. Patients who got their first dose within eight hours did show less damage.

So the protein has a real research history, several studies that missed their main target, and one recent result in a smaller group. That is a good deal less than “it worked in humans” implies, and none of it is evidence about the seven amino acid piece being sold anyway.

What the BPC-157 research actually shows

Nearly all of it is rats and lab dishes.

In rats with a cut Achilles tendon, the tendon healed faster and ended up stronger. In another rat study it improved how well tendon reattached to bone. In lab dishes it made tendon cells grow out and move faster, and more so at higher doses.

The human record, in full

You will often read that BPC-157 was proven safe in human trials for inflammatory bowel disease. Something real sits behind that claim, and it is smaller than it sounds.

A Croatian drug company developed the identical molecule under a different product name in the early 2000s. A first-stage safety study in healthy men found it well tolerated. A follow-up study in people with mild to moderate ulcerative colitis was run and presented at a conference in 2005, but the results were never published as a full paper, and the company dropped the programme.

Everything since then is small. A safety study registered around 2015 whose results were never published. A 2021 report on 16 patients with knee pain. A 2024 report on 12 women with bladder pain. A 2025 report on two people given it through an IV.

That is roughly thirty people, none of them in a study with a comparison group, and no published trial testing whether it works for anything.

Who did the research matters here. A 2026 review counted up authorship across the BPC-157 literature and found that more than 80% of published studies trace to a single university group in Croatia. The animal work is large in volume and narrow in origin, and very little of it has been repeated by anyone else.

They work in different ways

The pairing suggests two tools doing similar jobs, and the two mechanisms have almost nothing to do with each other.

BPC-157 is about blood supply, meaning new vessels and better signalling into the injured area.

Thymosin beta-4 is about cell movement, meaning cells rearranging themselves and crawling across a gap.

You can make an argument on paper for combining them, and nobody has tested it. No published study, in dishes, animals, or people, has looked at the two together. What the pairing actually traces back to is both compounds being sold by the same suppliers.

The doses are nothing alike

BPC-157 is commonly taken at around 250 to 500 mcg, once or twice a day. TB-500 is commonly taken at around 2 to 5 mg, once or twice a week.

One is a small amount taken constantly, the other a bigger amount taken occasionally.

Two things follow. Anyone reading instructions for both is switching between micrograms and milligrams in the same sitting, which is exactly how the thousand-fold dosing error happens. And the two vials run out at different times, so work out the weekly cost of each separately.

Neither range comes from a study designed to find the right dose. Both are community habit, and there is a tell that they are: across retailer sites, compounds in this group keep landing on the same round numbers. Real dose-finding produces awkward figures, because it follows what the data did. Numbers that look tidy across a dozen different compounds are numbers somebody chose.

Taking BPC-157 by mouth

Some people swallow it instead of injecting, which is unusual for a peptide. The reasoning is that something that comes from a stomach protein might survive the stomach.

The first half holds up: BPC-157 does appear to survive stomach acid, and rats given it in drinking water show effects.

The second half has never been shown. The only proper study of where the compound goes in the body tested injection into a vein and into muscle, in rats and dogs. It found the compound clears out fast, in under half an hour. It did not test swallowing at all, and nobody has measured any of this in a human.

Surviving your stomach and reaching your bloodstream in useful amounts are separate claims, and only the first has support behind it. The better case for swallowing it is for gut problems, not for a knee.

Where these stand legally

Compounding pharmacies

In 2023 the FDA put both compounds on a list of ingredients that may carry significant safety risks, so pharmacies could not use them. The reasons given for BPC-157 were that it might trigger an immune reaction depending on how it is given, that there are complications around impurities and confirming what the ingredient actually is, and that safety information is limited.

In April 2026 both were taken off that list, along with ten other peptides. This did not make them legal. The removal was a paperwork step, neither compound is on the approved list pharmacies can actually use, and both were sent back for an advisory committee review at the end of July 2026. That review has just happened as this was written, so check the current position before relying on any of this.

Approval

Neither is approved for any medical use in the US, Europe, or Australia.

Vendors

The FDA has sent warning letters to companies selling research-labelled peptides for people to use, and has tightened up on imports.

Tested sport

Both are banned at all times, in and out of competition.

This needs saying plainly, because a review published in 2025 claims BPC-157 is no longer banned, and that claim is simply incorrect. It is named on the current banned list, as is thymosin beta-4 and products derived from it, with TB-500 given as the example. Both can be detected by current testing, and athletes have been sanctioned for both.

What neither one is proven to do

• Neither has a proper trial showing it works, for the version sold online.
• Neither is approved for any use anywhere.
• Neither has been tested alongside the other.
• Neither has long-term safety data in people. That matters more than usual here, because both are supposed to work by encouraging tissue to grow.

Shared cautions

Active cancer

Both are avoided as a precaution. BPC-157 encourages new blood vessels and thymosin beta-4 encourages cells to move, and tumours use both of those. The concern is theoretical: no study has shown either compound causing or spreading cancer, and no study has been designed to check properly either, so the absence of evidence is not reassurance.

Pregnancy

No safety information exists.

What is actually in the vial

This risk is separate from the compounds themselves and is probably the bigger one. Both sell through unregulated channels where products have turned up mislabelled, containing the wrong sequence, weaker than stated, or contaminated. You are holding a substance and a claim about it.

For both, new lumps and signs of an allergic reaction mean stop and get medical attention rather than wait and see.

Side by side

Common questions